D-核糖复方制剂辅助治疗新型冠状病毒肺炎的临床研究  

Clinical Study on Adjuvant Therapeutically Treatment on COVID-19 with Compounded D-ribose

作　　者：肖爱爱 汤惠茹 姜雯[3] 张宁 韩军 洪强 王正平 XIAO Aiai;TANG Huiru;JIANG Wen;ZHANG Ning;HAN Jun;HONG Qiang;WANG Zhengping(Institute of BioPharmaceutical Research,Liaocheng University,Liaocheng 252059,China;Shenzhen Cheerland Watson Precision Medicine Co.Ltd.,Shenzhen 518000,China;Liaocheng People s Hospital,Liaocheng 252000,China;Liaocheng High-tech Biotechnology Co.,Ltd.,Liaocheng 252000,China;Huazhong University of Science and Technology Union Jiangbei hospital,Wuhan 430000,China;Haimen Pharmaceutical Technology Co.,Ltd.,Nantong 226133,China)

机构地区：[1]聊城大学生物制药研究院,山东聊城252059 [2]深圳乐土沃森精准医疗公司,广东深圳518000 [3]聊城市人民医院,山东聊城252000 [4]聊城高新生物技术有限公司,山东聊城252000 [5]华中科技大学协和江北医院,湖北武汉430000 [6]海门品尚医药科技有限公司,江苏南通226133

出　　处：《聊城大学学报（自然科学版）》2023年第1期93-98,共6页Journal of Liaocheng University:Natural Science Edition

基　　金：国家自然科学青年基金项目(82001286);山东省抗体制药协同创新中心(聊城大学)开放课题(CIC-AD1814,CIC-AD1839);校企合作项目(K20LD0901)资助。

摘　　要：目的:评价在遵照《新型冠状病毒肺炎诊疗方案-试行第五版》的常规治疗基础上,通过加用口服D-核糖复方制剂治疗新型冠状病毒肺炎(COVID-19)的临床疗效和患者的恢复情况。方法:采用前瞻性对照临床研究设计,纳入76例COVID-19患者,在进行常规治疗的同时,联合使用D-核糖复方制剂,以观察其对患者康复的促进作用。纳入的76例COVID-19患者中,常规治疗的8例为对照组,常规治疗联合D-核糖复方制剂的68例为治疗组。比较2组患者治疗7天后的体温、心率、血压、呼吸频率、血氧饱和度、疲乏程度和睡眠质量等基本指标改善情况,并评价治疗效果。结果:体温、心率、呼吸频率、血氧饱和度组间比较差异无统计学意义(p>0.05);治疗第3天后,治疗组患者疲乏程度及睡眠质量较对照组发生显著改善(p<0.05)。结论:采用D-核糖复方制剂联合常规治疗对COVID-19患者有一定的辅助治疗效果,表现在其能够明显地改善患者的疲乏程度、睡眠质量,提高临床疗效,达到使患者提前出院的目的。Objective:To evaluate the clinical efficacy and recovery of Corona Virus Disease 2019(COVID-19)treated with compounded D-ribose as adjuvant therapeutically treatment in addition to the routine treatment of COVID-19 based on《The fifth trial edition of diagnosis and treatment of COVID-19》.Methods:76 patients with COVID-19 were enrolled in a prospective controlled clinical study design.Besides the routine treatment,the patients were treated with compounded D-ribose to observe its promoting effect on the rehabilitation of the patients.Among the 76 patients with COVID-19,8 patients only received routine treatment as the control group,and 68 patients received routine treatment combined with compounded D-ribose orally as the intervention group.The basic indexes such as body temperature,heart rate,blood pressure,respiratory rate,blood oxygen saturation,fatigue and sleep quality were compared between the two groups after 7 days of treatment,and the therapeutic effect was evaluated.Results:there was no significant difference in body temperature,heart rate,respiratory rate and blood oxygen saturation between the two groups(p>0.05),but the fatigue and sleep quality in the intervention group were significantly better than those in the control group after 3 days of treatment(p<0.05).Conclusion:The use of compounded D-ribose in addition to the routine treatment has a certain adjuvant therapeutic effect on patients with COVID-19,which can significantly improve the status of fatigue,sleep quality of patients as well as the clinical efficacy as shown by the early discharge of patients.

关 键 词：COVID-19 D-核糖复方制剂 疲劳 睡眠质量 

分 类 号：R459.3[医药卫生—治疗学]